<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02716181</url>
  </required_header>
  <id_info>
    <org_study_id>166-2015</org_study_id>
    <nct_id>NCT02716181</nct_id>
  </id_info>
  <brief_title>Efficacy of the &quot;Атопик Soothing Cream&quot; in Children With Mild to Moderate Atopic Dermatitis</brief_title>
  <official_title>A Double-Blind Randomized Placebo-Controlled Trial to Evaluate the Efficacy of the &quot;Атопик Soothing Cream&quot; in Children With Mild to Moderate Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avanta Trading Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samara State Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prof. Zvulunov Alex, Pediatric Dermatology Clinic, Kfar-Saba, Israel.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Avanta Trading Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Double-Blind Randomized Placebo-Controlled Trial to Evaluate the Efficacy of the &quot;Атопик
      Soothing Cream&quot; in Children with Mild to Moderate Atopic Dermatitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      &quot;Атопик Soothing Cream&quot; is a lipid complex composed of barley grain, Butyrospermum Parkii and
      Argania Spinosa Kernel oil, in a mixture with panthenol and bisabolol.

      Investigators concure that combination of these substances in &quot;Атопик Soothing Cream&quot; will be
      efficacious non-steroidal treatment of Atopic Dermatiti ( AD).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 29, 2016</start_date>
  <completion_date type="Actual">May 1, 2017</completion_date>
  <primary_completion_date type="Actual">May 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigators' Global Assessment score</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eczema Area &amp; Severity Index (EASI)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus intensity</measure>
    <time_frame>28 days</time_frame>
    <description>Visual Analog Scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Trans-Epidermal Water Loss</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stratum Corneum Capacitance</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>&quot;Атопик&quot; phase 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For the first phase of the study, subjects will be randomized to receive treatment with &quot;Атопик Soothing Cream&quot;.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - phase 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>For the first phase of the study, subjects will be randomized to receive treatment with Placebo Cream.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Атопик&quot; phase 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The second phase of the study is an open-label extension with all subjects receiving &quot;Атопик Soothing Cream&quot;.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - phase 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The second phase of the study is an open-label extension with all subjects receiving &quot;Атопик Soothing Cream&quot;.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>&quot;Атопик Soothing Cream&quot;</intervention_name>
    <description>Topical application of a study cream to involved skin areas twice a day.</description>
    <arm_group_label>&quot;Атопик&quot; phase 1</arm_group_label>
    <arm_group_label>Placebo - phase 1</arm_group_label>
    <arm_group_label>&quot;Атопик&quot; phase 2</arm_group_label>
    <arm_group_label>Placebo - phase 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Topical application of a study placebo cream to involved skin areas twice a day.</description>
    <arm_group_label>&quot;Атопик&quot; phase 1</arm_group_label>
    <arm_group_label>Placebo - phase 1</arm_group_label>
    <arm_group_label>&quot;Атопик&quot; phase 2</arm_group_label>
    <arm_group_label>Placebo - phase 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have clinical diagnosis of mild to moderate atopic dermatitis (AD) at both
             Screening and Baseline Visits, defined as IGA score of 2 or 3 ( Rothe 1996) or EASI
             score between 2 and 21 (Leshem 2015)

          -  Must have AD affecting &gt;5% total body surface area (TBSA) at Baseline

          -  History of AD for at least 3 months prior to Baseline

          -  Informed consent/assent in accordance with the International Conference on
             Harmonization (ICH) Good Clinical Practice (GCP) Guideline and applicable regulations,
             before completing any study-related procedures

        Exclusion Criteria:

          -  Use of topical corticosteroids within 7 days prior to Baseline

          -  Use of systemic corticosteroids, topical calcineurin inhibitors, photo-therapy (PUVA,
             UVB) or immunosuppressive therapy (eg, cyclosporine) within 14 days prior to Baseline

          -  Subjects that require systemic therapy for the treatment of AD

          -  Use of systemic anti-infective or antibiotic treatment within 14 days prior to
             Baseline

          -  Subjects who present with clinical conditions other than AD that may interfere with
             the evaluation (eg, generalized erythroderma, acne, Netherton's Syndrome, psoriasis)

          -  Any clinically significant skin disease other than AD

          -  Secondary infection of AD (bacterial, viral or fungal) within the skin area under
             study or open skin infections in any area at Baseline

          -  History of severe anxiety and/or depression; any history of suicide attempt

          -  Subjects with a history of human immunodeficiency virus (HIV) as determined by medical
             history

          -  Subjects who, in the opinion of the Investigator(s), would be non-compliant with the
             visit schedule or study procedures

          -  Participation in any other investigational trial within 6 weeks of Baseline, or during
             study conduct

          -  Chronic condition(s) which are either unstable or not adequately controlled

          -  Drug or alcohol abuse, mental dysfunction, or other condition limiting the subject's
             ability to be compliant with study-related procedures

          -  Any medical condition that may, in the opinion of the Investigator(s), preclude the
             safe administration of test article or safe participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Zvulunov, MD</last_name>
    <role>Study Director</role>
    <affiliation>Prof. Alex Zvulunov, Pediatric Dermatology Clinic, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Allergy-Immunology, Department of Pediatrics, Institute of Professional Education</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Maurya AK, Singh M, Dubey V, Srivastava S, Luqman S, Bawankule DU. α-(-)-bisabolol reduces pro-inflammatory cytokine production and ameliorates skin inflammation. Curr Pharm Biotechnol. 2014;15(2):173-81.</citation>
    <PMID>24894548</PMID>
  </reference>
  <reference>
    <citation>Ebner F, Heller A, Rippke F, Tausch I. Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol. 2002;3(6):427-33. Review.</citation>
    <PMID>12113650</PMID>
  </reference>
  <results_reference>
    <citation>Jirabundansuk P, Ophaswongse S, Udompataikul M. Comparative trial of moisturizer containing spent grain wax, Butyrospermum parkii extract, Argania spinosa kernel oil vs. 1% hydrocortisone cream in the treatment of childhood atopic dermatitis. J Med Assoc Thai. 2014 Aug;97(8):820-6.</citation>
    <PMID>25345257</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2016</study_first_submitted>
  <study_first_submitted_qc>March 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2016</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>Topical therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Clinical parameters at the entry and at the end of study might be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

